<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00219700</url>
  </required_header>
  <id_info>
    <org_study_id>PL-IB-002</org_study_id>
    <nct_id>NCT00219700</nct_id>
  </id_info>
  <brief_title>Ibuprofen-PC Compared With Ibuprofen in a GI Safety Trial</brief_title>
  <official_title>Phase II, Randomized, Blinded Study of Ibuprofen-PC and Ibuprofen in Patients With Osteoarthritis to Investigate Efficacy and Gastrointestinal Toxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PLx Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Texas Higher Education Coordinating Board</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PLx Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and efficacy of 3 x 800 mg/day IBU-PC assessed by endoscopy and
      incidence of adverse events
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lanza score assessed by endoscopy at baseline and after six weeks of treatment to measure GI safety.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>WOMAC and VAS scores every two weeks until end of treatment to measure efficacy.</measure>
  </secondary_outcome>
  <enrollment>125</enrollment>
  <condition>Osteoarthritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen-PC</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  moderate osteoarthritis in the hip and/or knee requiring chronic pain medication

          -  others per protocol

        Exclusion Criteria:

          -  sensitivity to NSAIDs and lecithin

          -  hypertension

          -  history of GI and other specific problems

          -  use of medications and other criteria per the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://www.plxpharma.com</url>
  </link>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2005</study_first_submitted>
  <study_first_submitted_qc>September 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>November 25, 2008</last_update_submitted>
  <last_update_submitted_qc>November 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2008</last_update_posted>
  <responsible_party>
    <name_title>Ron Zimmerman/President</name_title>
    <organization>PLx Pharma</organization>
  </responsible_party>
  <keyword>NSAID-PC</keyword>
  <keyword>IBU-PC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

